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Abstract - Osteoporosis and avascular necrosis 
(AVN) are long-lasting and debilitating complica-
tions of hematopoietic stem cell transplantation 
(HSCT).  
We describe the magnitude of bone loss, AVN 
and impairment in osteogenic cell compartment fol-
lowing autologous (auto) and allogeneic (allo) 
HSCT, through the retrospective bone damage re-
valuation of 100 (50 auto- and 50 allo-HSCT) long-
term survivors up to 15 years after transplant.  Cur-
rent treatment options for the management of these 
complications are also outlined. 
We found that
 
auto- and allo-HSCT recipients 
show accelerated bone mineral loss and micro-
architectural deterioration during the first years after 
transplant.  Bone mass density (BMD) at the lumbar 
spine,
 
but not at the femur neck, may improve in 
some patients after HSCT, suggesting more pro-
longed bone damage in cortical bone. Phalangeal 
BMD values remained low for even more years, 
suggesting persistent bone micro-architectural altera-
tions after transplant.  The incidence of AVN was 
higher in allo-HSCT recipients compared to auto-
HSCT recipients.  Steroid treatment length, but not 
its cumulative dose was associated with a higher in-
cidence of bone loss. Allo-HSCT recipients affected 
by chronic graft versus host disease seem to be at 
greater
 
risk of continuous bone loss and AVN devel-
opment. Reduced BMD and higher incidence of 
AVN was partly related to a reduced regenerating 
capacity of the normal marrow osteogenic cell com-
partment.  
Our results suggest that all patients after auto-
HSCT and allo-HSCT should be evaluated for their 
bone status and treated with anti-resorptive therapy 
as soon
 
as abnormalities are detected.  
 
 Keywords -    osteoporosis, hemopoietic stem 
cell transplantation, bisphosphonates 
 
 
    I.  INTRODUCTION 
 
 Patients with several malignant and non-malignant 
hematological diseases such as acute leukemia, especially 
acute lymphoblastic leukemia in children, lymphoma, 
myeloma, major thalassemia and severe hemophilia are at 
risk for bone damage
 
[1-15]. Moreover, various hemato-
logical related therapies, including chemotherapy, gluco-
corticoids, hormonal agents and newer targeted therapies 
may affect bone health resulting in long-term skeletal dis-
orders, particularly osteopenia, osteoporosis, fractures and 
avascular necrosis (AVN) [16-23].  
 In the last four decades the number of autologous (au-
to) and allogeneic (allo) hematopoietic stem cell trans-
plantation (HSCT) in the treatment of malignant and non-
malignant hematological diseases has grown together with 
a progressive increase of long-term survivors due to a de-
crease of transplant-related mortality.  
With the number of long-term survivors after HSCT pro-
gressively increasing, early and late complications of this 
procedure have gained much more attention. Osteoporo-
sis, fractures and AVN leading to pain and disability rep-
resent some of more frequent complications which may 
worsen the quality of life of long-term survivors after 
HSCT [24]. 
The aim of this review is to describe the magnitude of 
bone loss and AVN following HSCT and their current 
management, as well as to examine the role of marrow 




II. METHODOLOGY  
 
Subjects 
A retrospective cohort of 100 patients who had un-
dergone auto- (n=50) or allo-HSCT (n=50) for a hemato-
logical malignancy, and had survived free of disease for 
one or more years post-HSCT, was evaluated in this 
study. Clinical features of the patients and underlying dis-
eases are summarized in Table 1. Their age at transplanta-
tion ranged between 20 and 52 years (median, 32) and 
their post-HSCT follow-up lasted from 1 to 15 years (me-
dian, 6). Primary diseases were acute (n=44) or chronic 
(n=13) myeloid leukemia, Hodgkin disease (n=17), non-
Hodgkin lymphoma (n=12), and multiple myeloma 
(n=14). Auto- and allo-HSCT groups were similar for age, 
body mass index (BMI), and time elapsed from transplant.  
 
Measurement of bone mass density 
Bone mass density (BMD) was measured by dual en-
ergy X-ray absorptiometry (DEXA) at lumbar spine (L1-
L4) and femoral neck, and by quantitative phalangeal ul-
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trasonometry (P-QUS), as previously described [25].  
BMD was expressed as Z scores, that assess standard de-
viation (SD) of patients’ BMD compared with normal 
values from age and sex-matched controls, respectively. 
Osteopenia and osteoporosis were defined by a Z score 
below  –1 and –2.5 SD, respectively [26, 27].  
Diagnosis of AVN suspected cases was documented 
by magnetic resonance imaging (MRI). 
 
Measurement of osteogenic precursors  
The marrow compartment of osteogenic precursors 
was evaluated in 35 auto- and allo-HSCT recipients by 
growing colony-forming units-osteogenic cells (CFU-O), 
defined by their ability to express alkaline phosphates ac-
tivity from enriched mesenchymal stem cells, as previous-
ly described [28].  
 
Statistical analysis 
 Statistical analysis of the data (expressed as mean ± 
SD and ± SEM as appropriate throughout the text and in 
figures) was performed using paired students t-tests for 
non-parametric variables. Statistical significance was con-
sidered for p < 0.05. 
 
  
III. RESULTS  
 
Bone mineral density in transplanted patients 
At the time of testing (mean follow-up after HSCT: 
65 months; range: 1-15 years),  lumbar spine (Z score 
mean value: -0.4 and -0.9 in auto- and in allo-HSCT re-
cipients, respectively; p<0.05), femoral neck (-0.6 and -
1.4 in auto- and in allo-HSCT recipients, respectively; 
p<0.05) and phalanges (-1 and -1.5 in auto- and in allo-
HSCT recipients, respectively; p<0.05) BMD were signif-
icantly reduced in comparison with BMD of 100 healthy 
controls (p<0.001 in all examined sites) (Figure 1). 
By DEXA and P-QUS, we could not document sig-
nificant correlation between BMD reduction and age at 
the time of HSCT, cumulative dose of prednisone and cy-
closporine A, length of steroid treatment and follow-up 
after BMT (Table 1). Development of acute and chronic 
graft versus-host disease (GVHD), requiring long lasting 
high dose steroid treatment, was associated with a more 






     Hematopoietic stem cell transplant   Controls 
      Allogeneic    Autologous  
Number 50 50 100 
Age (years) 32±12* 41±12 36±13 
Female/Male 23/27 21/29 43/57 
Diagnosis: 
     AML  
     CML  
     HD  
     NHL  














Follow-up (months) 17.5±17 16.9±11 - 








 Steroid dose (g/m2)        
duration (months) 














Abbreviations: AML, Acute Myeloid Leukemia; CML, Chronic Myeloid 
Leukemia; HD, Hodgkin’ Disease; NHL, Non Hodgkin Lymphoma; 
MM, Multiple Myeloma; BMI, Body Mass Index; BU-CY2, Busulfan – 
Cyclophosphamide; BEAM, Carmustine - Etoposide – Cytarabine - 
Melphalan; TTCY, ThioTepa – Cyclophosphamide; MEL, Melphalan;  
CsA, Cyclosporine A. Symbols: °, expressed as prednisone equiva-
lents.;*, p<0.05 vs  autologous stem cell transplantation.  
 
Fig. 1. Bone mass evaluation in transplanted patients versus normal controls. 
Mean values of Z score (expressed as mean ± SD) at lumbar spine (L1-L4), femoral neck and phalanges, in 
allogeneic and autologous hemopoietic stem cell transplantation (auto- and allo-HSCT) recipients. Each column represents the mean values of Z scores, 
vertical bars represent the standard error of mean. 
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Auto- and allo- HSCT recipients who were evaluated 
> 3 years after transplant had significantly higher (p< 
0.001) lumbar BMD than patients evaluated < 3 years. On 
the other hand, no difference was seen in HSCT recipients 
evaluated before or after 3 years since transplant at the 
femoral neck and phalanges (data not shown). Phalangeal 
BMD values remained low even after more than 6 years 
(data not shown). 
 
Avascular necrosis in transplanted patients 
Eight patients developed AVN, 1 to 15 years (median, 
28) following HSCT: 6 (12%) after allo-HSCT and 2 
(4%) after auto-HSCT (p<0.05). A total of 15 joints were 
affected and all patients had femoral head involvement, 
which required surgical management in 4 of them. All but  
one patient affected by AVN in the allogeneic setting 
were suffering from chronic extensive GVHD; its exacer-
bation or recurrence was documented in 3/6 patients 
shortly (1-6 months) before the AVN diagnosis. Concern-
ing possible risk factors, AVN was related to allogeneic 
type of transplant, chronic extensive GVHD, longer ster-






Fig. 2. Number of colony forming units-osteogenic progenitors  
(CFU-O) in hematopoietic stem cell transplantation (HSCT) recipi-
ents and normal controls. 
Each orange and red dot represents an auto- and allo-HSCT recipient. 
Horizontal bars represent mean values, vertical bars represent the stand-
ard error of mean. 
 
 
Osteogenic compartment in transplanted patients 
The marrow compartment of osteogenic precursors, 
measured as CFU-O cells, was decreased 2 to 3- fold in 
auto- and allo-transplanted recipients compared to normal 
donors (30±6 and 21±5 in auto- and allo-HSCT recipients, 
respectively, vs 55±4/10
5 
cells plated in normal controls; 
all p<0.001) (Figure 2). Analyzing the effect of the time 
elapsed since HSCT on marrow CFU-O numbers, we 
found the marrow CFU-O compartment markedly deplet-
ed during the first  years after transplant (data not shown). 
Between 6 and 15 years, the mean marrow CFU-O cell 
number tended to increase (13 ±3 vs 33 ±5 before and af-
ter 3 years, respectively; p<0.05), although most patients 
showed a number of CFU-O permanently below that ob-
served in normal controls. CFU-O growth correlated sig-
nificantly with lumbar, femoral and phalangeal bone loss 
(all p<0.01). Chronic GVHD was correlated with a lower 
number of CFU-O colonies in vitro (p<0.01).  
Finally, almost all transplanted patients who had 
AVN showed a number of CFU-O below that observed in 
transplanted patients without this complication (CFU-O: 
24.5±3 vs 12.4±4 in HSCT patients without and with os-
teonecrosis, respectively; p<0.05) (Figure 3). 
 
 
Fig. 3. Number of colony-forming units-osteogeneic progenitors  
(CFU-O) in auto- (orange dot) and allo (red dot) hemopoietic stem 
cell transplantation (HSCT) recipients with and without osteonecro-
sis. 
Each dot represents a subject studied. Horizontal bars represent mean 
values, vertical bars represent the standard error of mean. 
     
 
     IV. DISCUSSION 
 
 Osteopenia and osteoporosis are relatively common 
early complications of auto- and allo-HSCT. They are at-
tributable to the influence of multiple factors including 
myeloablative conditioning regimens, huge cytokine re-
lease at the time of transplant, altered kidney, liver and 
bowel function resulting in reduced intake and altered me-
tabolism of calcium and vitamin D, frequent gonadal fail-
ure and, in allogeneic HSCT setting, long-lasting high-
dose steroids and cyclosporin-A [29, 30]. In the current 
study, we retrospectively followed 100 consecutive pa-
tients who had undergone auto- and allo-HSCT and sur-
vived one or more years. As already suggested by our and 
other studies, we documented a marked decrease in BMD 
after auto- and allo-HSCT both at the lumbar spine (25%) 
and even more at the femoral neck (50%). We have con-
firmed that a significant decrease in BMD at lumbar and 
femoral neck level appears early after transplant and 
seems to continue over the first 3 years with no further 
deterioration afterwards.  
Although bone density is among the strongest predic-
tors of the mechanical behavior of trabecular bone, the 
whole bone strength is determined also by bone quality.  
Apart from bone mineralization, bone architecture, turno-
ver, and damage accumulation also account for bone qual-
ity. Several data show that trabecular micro-architecture 
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influences trabecular bone strength. Early bone loss may 
consist of both demineralization and architectural damage 
with associated organic matrix deficit. DEXA measures 
bone density and mineralization but does not provide in-
formation on architectural damage and bone formation 
[31]. High-resolution computed tomography and MRI al-
low for three-dimensional assessment of trabecular struc-
ture, but their use in the routine clinical practice for diag-
nosis and follow-up of bone damage is limited, being too 
costly and time-consuming. Ultrasonographic evaluation 
by phalangeal QUS is a safe and less expensive proce-
dure, which permits to assess more physical properties of 
bone tissue and to account for more structural changes 
than DEXA [32]. Phalangeal QUS allows to evaluate 
bone density and elasticity, trabecular orientation and cor-
tical-to-trabecular ratio, all of which are influenced by 
mineral content and organic matrix. In HSCT recipients, 
we have further confirmed by DEXA that, while mineral-
ization seems to improve at trabecular rich sites such as 
lumbar spine, no improvement was detected at cortical 
bone such as femoral neck; in addition, no improvement 
was revealed by phalangeal QUS even several year after 
transplant. 
Allo- and auto-HSCT recipients were mostly pooled 
together in several clinical studies on bone complications 
after HSCT, whereas there are considerable differences 
between these two settings. The differences consist in a 
higher grade of immunologic derangement and more pro-
longed use of immunosuppressive treatments needed to 
avoid development of acute and chronic GVHD in the al-
logeneic setting [27]. Apart from women which may ex-
perience ovarian failure after auto- and allo-HSCT, in the 
setting of allogeneic HSCT, we have also documented 
that an important high risk factor is the development of 
chronic GVHD requiring prolonged high-dose of steroids 
[33-37]. 
Avascular necrosis (AVN) has been described in 3-
41% of patients who had received an organ transplant, 
with femoral head being the prevalent localization [38]. 
AVN is the result of multiple triggering factors such as 
metabolic disorders, local vascular damage with transient 
or permanent loss of blood supply to the bone, increased 
intra-osseous pressure and mechanical stress leading to 
demineralization, and death of trabecular bone and col-
lapse.  
The process is mostly progressive, resulting in joint 
destruction within three to five years if left untreated. 
AVN occurred in 8 of 100 long-term survivors (8%), 
within 3-15 years (median, 3.6) after-HSCT, all but two 
of them having received an allo-HSCT. Surgical treatment 
was required in half of HSCT patients because of func-
tional limitations.  A significant statistical association was 
found between AVN occurrence, allogeneic type of trans-
plant, presence and grade of GVHD, steroid treatment 
length, and cumulative dose [17, 39]. In addition, we have 
recently reported a close relationship between AVN oc-
currence and flare up of chronic GVHD [38].  
Bone remodeling, specifically the balance between 
formation and resorption, is the biologic process that me-
diates architectural changes influencing the whole bone 
strength. We have documented a marked and permanent 
quantitative and qualitative defect in the marrow osteo-
genic cell compartment, suggesting that inability to re-
store a normal number of osteoblastic precursors in the 
bone microenvironment may account at least in part for 
severe bone damage after auto- and allo-HSCT. The re-
duced repopulating capacity of osteoblast precursors after
 
HSCT is likely related to the effects of chemothera-
py/radiotherapy,
 
to the concomitant endocrine disorders, 
immunosuppressive treatments,
 
and alteration in the bal-
ance of cytokines and growth factors.
  
According to the 
above described long-lasting deficit of osteogenic progen-
itors, we have recently documented within the bone mar-
row microenvironment of these HSCT recipients low os-
teoprotegerin (OPG) levels, exacerbated by a high ratio 
for receptor activator for nuclear kappa B ligand 
(RANKL)/OPG favouring bone resorption after HSCT 
(Figure 4) [40]. 
Few data are available so far on the treatment of bone 
loss in HSCT recipients. Early diagnosis of osteoporosis 
or early bone senescence in this particular population is a 
major aim to promptly start appropriate supportive 
measures, such as lifestyle modification, calcium and vit-
amin D supplementation or bisphosphonates. However, 
there is sufficient evidence that common preventive 
measures for bone loss, such as calcium and vitamin D 
supplements and sex steroid replacement, are ineffective 
in HSCT recipients.  Bisphosphonates are currently the 
most effective inhibitors of osteoclastic bone resorption; 
they directly impair the ability of osteoclasts to adhere to 
the bone surface, and inhibit osteoclast activity by de-
creasing osteoclast progenitor development and recruit-
ment and by promoting osteoclast apoptosis. In addition, 
recent evidences have been accumulated on the anabolic 
bone effects of bisphosphonates, enhancing osteoblast 
proliferation, and preventing osteoblast apoptosis [41-43]. 
Oral bisphosphonates, widely used for treating osteoporo-
sis, have been shown to improve bone BMD and decrease 
the rate of fractures in various patient populations [44]. 
However, the use of these drugs in the clinical routine of 
HSCT recipients is limited by their poor gastrointestinal 
tolerance, variable oral bioavailability and long-term 
compliance. We have previously reported that  zoledronic 
acid, given as three consecutive monthly doses of 4 mg 
each every years, is able to obtain a rapid and measurable 
increase of bone mass. Given the persistent bone loss at 
trabecular and cortical rich skeletal sites in HSCT recipi-
ents, zoledronic acid may be considered the treatment of 
choice in the near-transplant period for the prevention of 
bone loss. We also documented that beneficial effects on 
lumbar and femoral BMD of zoledronic acid treatment in 
HSCT patients were associated with a significant im-
provement of the osteogenic progenitors [28].
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Fig. 4. Critical factors involved in bone remodeling after hemopoietic stem cell transplantation. 
Chemotherapy, radiotherapy, gonadal failure, acute and chronic graft versus host disease (GVHD) and growth factors (such as fibroblast growth factor-
2 -FGF2-, insulin growth factor-1 -IGF1-)  may affect directly bone marrow microenvironment altering the capacity to synthesize osteoprotegerin 
(OPG) and receptor activator for nuclear kappa-B ligand (RANKL). In particular, high dose of steroids, cytokines, high levels of parathyroid hormone 
(PTH) and low levels of sexual hormones decrease OPG production by osteoblastic  progenitors, whereas pro-inflammatory cytokines (such as tumor-
necrosis factor-α -TNFα-, interleukin-1 -IL1- and interferon-γ -IFNγ -), long-lasting glucocorticoids, 1,25OH-vitamin D and PTH increase RANKL 
production by osteoblasts and T lymphocytes. All of these marrow microenvironment changes may increase RANKL/OPG ratio stimulating osteoclas-
tic activity and bone resorption. Symbols: Y, OPG;  blue O , RANKL;  U, RANK. 
 
In addition, we have recently documented in a small co-
hort of HSCT recipients that 1-year treatment with 
risedronate increases lumbar spine BMD and prevents 
bone loss at the femoral neck [44]. Clinical experience 
with the human monoclonal antibody anti-RANKL (deno-
sumab), which is documented to be effective in non meta-
static prostate and breast cancer as well as in postmeno-
pausal osteoporosis, as well as with the parathyroid hor-
mone derived peptides, with hormone analogues and se-
lective estrogen receptor modulators, is still limited in 
HSCT recipients [30, 45, 46]. 
 
 
V.  CONCLUSIONS 
 
In this study, we have confirmed that an accelerated 
and persistent multifactorial bone loss occurs in long-term 
survivors after HSCT, being more severe in the allogeneic 
setting. Moreover, osteoporosis is more frequent than 
AVN in patients after allo-HSCT.  Several new risk fac-
tors have been identified and include
 
a dysregulation of 
the immune system occurring during acute and chronic 
GVHD and their treatments, persistently reduced regener-
ating capacity of normal osteogenic cell compartment, 




DEXA bone density testing remains an accurate 
method to detect bone loss in HSCT recipients. Since 
phalangeal QUS is a safe and easy method, it should be 
more frequently used for early recognition and monitoring 
of BMD reduction as well as for decision-making in 
transplanted patients who may need specific therapy. Oral 
and parenteral bisphosphonates are currently the only 
treatments able to prevent and treat accelerated bone mass 
senescence after transplant. The choice between oral or 
intravenous bisphosphonate therapy in patients who had 
undergone HSCT should be made on the basis of individ-
ual clinical conditions, including presence, grading and 
localization of GVHD as well as prevalent site of bone 
loss. Oral risedronate and intermittent short course of 
zoledronic acid were easily manageable and effective in 
increasing densitometric values at trabecular skeletal 
sites. Zoledronic acid was the only therapy that improved 
also femoral BMD. At least part of these effects may be 
related to the bisphosphonates’ ability to partly restore the 
persistent post-transplant reduction of osteogenic progeni-
tors. Despite the evidence of only
 
partial effectiveness of 
preventive anti-resorptive treatments,
 
it is reasonable to 
start administration of these drugs before
 
or at the time of 
HSCT in all patients, as soon
 
as bone abnormalities are 
detected, and continue them at least for the
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